Azienda Ospedaliero, Universitaria Pisana
Quick facts
Phase 3 pipeline
- Baricitinib Oral Tablet · Immunology
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Phase 1 pipeline
- Fibrates · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Ospedaliero, Universitaria Pisana portfolio CI brief
- Azienda Ospedaliero, Universitaria Pisana pipeline updates RSS
Frequently asked questions about Azienda Ospedaliero, Universitaria Pisana
What is Azienda Ospedaliero, Universitaria Pisana's pipeline?
Azienda Ospedaliero, Universitaria Pisana has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Baricitinib Oral Tablet.
Related
- Sector hub: All tracked pharma companies